Tat protein based HIV vaccine - Vaxxit

Drug Profile

Tat protein based HIV vaccine - Vaxxit

Alternative Names: TatImmune

Latest Information Update: 16 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Istituto Superiore di Sanita
  • Developer VAXXIT
  • Class AIDS vaccines
  • Mechanism of Action Immunomodulators; Tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 10 May 2016 VAXXIT has patent protection for the Tat-based HIV vaccine worldwide
  • 09 May 2016 Phase-II clinical trials in HIV infections (Treatment-experienced) in Italy (unspecified route)
  • 09 May 2016 Phase-II clinical trials in HIV infections (Treatment-experienced) in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top